close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

12.72 -0.22 (-1.70%)
Streaming Delayed Price Updated: 9:47 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? ↗
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch. 
Via The Motley Fool
Topics Artificial Intelligence
Which stocks are moving on Friday? ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts ↗
Via Chartmill
Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Product ↗
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool
News headline image
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? ↗
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare. 
Via The Motley Fool
News headline image
Omeros (OMER) Q4 2025 Earnings Transcript ↗
Omeros (OMER) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Derivatives
News headline image
Omeros (OMER) Q1 2026 Earnings Transcript ↗
Omeros (OMER) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Omeros Q1 Earnings Call Highlights ↗
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic... 
Via MarketBeat
Topics Earnings
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz. 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? ↗
Yartemlea shipments to wholesalers are expected in the third week of January. 
Via Stocktwits
News headline image
Why Omeros Stock Skyrocketed Today ↗
The company is on the brink of commercializing a unique medication. 
Via The Motley Fool
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗
The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking. 
Via Stocktwits
Topics ETFs Economy Stocks
News headline image
Top movers in Wednesday's session ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside ↗
The drug was approved for use in adults and children aged two years and older. 
Via Stocktwits
News headline image
Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug ↗
The FDA decision on Narsoplimab, its treatment for post–stem cell and bone marrow transplant complications, is officially due on December 26. 
Via Stocktwits
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. 
Via Stocktwits
Topics Intellectual Property
News headline image
Omeros (OMER) Q3 2025 Earnings Call Transcript ↗
Omeros (OMER) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Derivatives Earnings
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Examining the Future: Omeros's Earnings Outlook ↗
 
Via Benzinga
News headline image
Breakout Momentum Plays You Need to Know About ↗
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
News headline image
4 Biotech Stocks Lifting Off As Momentum Builds ↗
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.